Rebeca focuses her practice on general corporate and securities law, representing emerging and high-growth companies throughout the business life cycle. She assists clients with corporate matters, including entity formation, venture financings, mergers and acquisitions, public offerings, US Securities and Exchange Commission (SEC) reporting and compliance, and corporate governance.
Inmagene Biopharmaceuticals Announces Merger With Ikena Oncology
December 23, 2024
Cooley advised Inmagene Biopharmaceuticals, a privately held, global clinical-stage biotechnology company developing novel therapeutics for immunological and inflammatory diseases, on its definitive merger agreement with Ikena Oncology (Nasdaq: IKNA).